Mon, March 14, 2022

Tiago Fauth Maintained (ASND) at Buy with Increased Target to $194 on, Mar 14th, 2022

Tiago Fauth of Credit Suisse, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Increased Target from $188 to $194 on, Mar 14th, 2022.

Tiago has made no other calls on ASND in the last 4 months.



There are 6 other peers that have a rating on ASND. Out of the 6 peers that are also analyzing ASND, 1 agrees with Tiago's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Yaron Werber of "Cowen & Co." Initiated at Hold and Held Target at $136 on, Thursday, January 6th, 2022


These are the ratings of the 5 analyists that currently disagree with Tiago


  • David Lebowitz of "Morgan Stanley" Maintained at Buy with Decreased Target to $180 on, Monday, March 7th, 2022
  • Derek Archila of "Wells Fargo" Maintained at Buy with Decreased Target to $170 on, Thursday, March 3rd, 2022
  • Liana Moussatos of "Wedbush" Maintained at Buy with Decreased Target to $117 on, Thursday, March 3rd, 2022
  • Leland Gershell of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $170 on, Monday, February 14th, 2022
  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $190 on, Monday, November 15th, 2021